Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Talitha L Feenstra

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
International Journal of Chronic Obstructive Pulmonary Disease|November 16, 2017
Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sourcesMartine Hoogendoorn, Talitha L Feenstra, Melinde Boland, et al.
European Journal of Pharmacology|August 6, 2011
Costs and health effects of adding functional foods containing phytosterols/-stanols to statin therapy in the prevention of cardiovascular diseaseSimone R B M Eussen, Talitha L Feenstra, Ido B Toxopeus, et al.
BMC Public Health|October 25, 2014
Long-term health outcomes and cost-effectiveness of a computer-tailored physical activity intervention among people aged over fifty: modelling the results of a randomized controlled trialDenise A Peels, Rudolf R Hoogenveen, Talitha L Feenstra, et al.
Diabetes, Obesity & Metabolism|December 30, 2020
Prediction of mortality and major cardiovascular complications in type 2 diabetes: External validation of UK Prospective Diabetes Study outcomes model version 2 in two European observational cohortsEva Pagano, Stefan R A Konings, Daniela Di Cuonzo, et al.
Acta Diabetologica|April 21, 2022
The transferability and validity of a population-level simulation model for the economic evaluation of interventions in diabetes: the MICADO modelSajad Emamipour, Eva Pagano, Daniela Di Cuonzo, et al.
Oncotarget|May 8, 2018
Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: a cost-effectiveness studyRositsa G Koleva-Kolarova, Marcel J W Greuter, Talitha L Feenstra, et al.
Pharmacoeconomics|June 10, 2023
Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP RegistryXinyu Li, Rudolf Hoogenveen, Mohamed El Alili, et al.
Plos Medicine|February 8, 2008
Lifetime medical costs of obesity: prevention no cure for increasing health expenditurePieter H M van Baal, Johan J Polder, G Ardine de Wit, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 16, 2017
External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling MeetingMartine Hoogendoorn, Talitha L Feenstra, Yumi Asukai, et al.
Diabetologia|August 1, 2020
A personalised screening strategy for diabetic retinopathy: a cost-effectiveness perspectiveSajad Emamipour, Amber A W A van der Heijden, Giel Nijpels, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
International Journal of Chronic Obstructive Pulmonary Disease|November 16, 2017
Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sourcesMartine Hoogendoorn, Talitha L Feenstra, Melinde Boland, et al.
European Journal of Pharmacology|August 6, 2011
Costs and health effects of adding functional foods containing phytosterols/-stanols to statin therapy in the prevention of cardiovascular diseaseSimone R B M Eussen, Talitha L Feenstra, Ido B Toxopeus, et al.
BMC Public Health|October 25, 2014
Long-term health outcomes and cost-effectiveness of a computer-tailored physical activity intervention among people aged over fifty: modelling the results of a randomized controlled trialDenise A Peels, Rudolf R Hoogenveen, Talitha L Feenstra, et al.
Diabetes, Obesity & Metabolism|December 30, 2020
Prediction of mortality and major cardiovascular complications in type 2 diabetes: External validation of UK Prospective Diabetes Study outcomes model version 2 in two European observational cohortsEva Pagano, Stefan R A Konings, Daniela Di Cuonzo, et al.
Acta Diabetologica|April 21, 2022
The transferability and validity of a population-level simulation model for the economic evaluation of interventions in diabetes: the MICADO modelSajad Emamipour, Eva Pagano, Daniela Di Cuonzo, et al.
Oncotarget|May 8, 2018
Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: a cost-effectiveness studyRositsa G Koleva-Kolarova, Marcel J W Greuter, Talitha L Feenstra, et al.
Pharmacoeconomics|June 10, 2023
Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP RegistryXinyu Li, Rudolf Hoogenveen, Mohamed El Alili, et al.
Plos Medicine|February 8, 2008
Lifetime medical costs of obesity: prevention no cure for increasing health expenditurePieter H M van Baal, Johan J Polder, G Ardine de Wit, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 16, 2017
External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling MeetingMartine Hoogendoorn, Talitha L Feenstra, Yumi Asukai, et al.
Diabetologia|August 1, 2020
A personalised screening strategy for diabetic retinopathy: a cost-effectiveness perspectiveSajad Emamipour, Amber A W A van der Heijden, Giel Nijpels, et al.
Pageof 8